Heteroaryl dihydroindolones as kinase inhibitors
US7977351B2 · kind B2 · utility
3Cited by
15References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 16, 2007 |
| Grant date | Jul 12, 2011 |
| Priority date | — |
| Expiry date | Jan 14, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound represented by the formula:wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification.Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.